Olk-Batz, C., Poetsch, A. R., Nöllke, P., Claus, R., Zucknick, M., Sandrock, I., Witte, T., Strahm, B., Hasle, H., Zecca, M., Stary, J., Bergstraesser, E., De Moerloose, B., Trebo, M., van den Heuvel-Eibrink, M. M., Wojcik, D., Locatelli, F., Plass, C., Niemeyer, C. M. ... European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS) (2011). Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood, 117(18), 4871-80. https://doi.org/10.1182/blood-2010-08-298968

Kratz, C. P., Rapisuwon, S., Reed, H., Hasle, H. & Rosenberg, P. S. (2011). Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. American Journal of Medical Genetics. Part C: Seminars in Medical Genetics, 157(2), 83-9. https://doi.org/10.1002/ajmg.c.30300

Coenen, E. A., Raimondi, S. C., Harbott, J., Zimmermann, M., Alonzo, T. A., Auvrignon, A., Beverloo, H. B., Chang, M., Creutzig, U., Dworzak, M. N., Forestier, E., Gibson, B., Hasle, H., Harrison, C. J., Heerema, N. A., Kaspers, G. J. L., Leszl, A., Litvinko, N., Lo Nigro, L. ... van den Heuvel-Eibrink, M. M. (2011). Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 117(26), 7102-11. https://doi.org/10.1182/blood-2010-12-328302

Maniecki, M. B., Hasle, H., Bendix, K. & Møller, H. J. (2011). Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leukemia Research, 35(6), e84-6. https://doi.org/10.1016/j.leukres.2011.01.025

Gustafsson, B., Hellebostad, M., Ifversen, M., Sander, B. & Hasle, H. (2011). Acute Respiratory Failure in 3 Children With Juvenile Myelomonocytic Leukemia. Journal of Pediatric Hematology/Oncology, 33(8), e363-e367. https://doi.org/10.1097/MPH.0b013e3182055e44

Wlodarski, M. W., Mötter, J., Gorr, T. A., Olk-Batz, C., Hasle, H., Dworzak, M., Niemeyer, C. M. & Flotho, C. (2011). Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood, 118(16), 4490-1. https://doi.org/10.1182/blood-2011-07-370684

Alford, K. A., Reinhardt, K., Garnett, C., Norton, A., Böhmer, K., von Neuhoff, C., Kolenova, A., Marchi, E., Klusmann, J.-H., Roberts, I., Hasle, H., Reinhardt, D., Vyas, P. & International Myeloid Leukemia-Down Syndrome Study Group (2011). Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood, 118(8), 2222-38. https://doi.org/10.1182/blood-2011-03-342774

Hasle, H. & Niemeyer, C. M. (2011). Advances in the prognostication and management of advanced MDS in children. British Journal of Haematology, 154(2), 185-95. https://doi.org/10.1111/j.1365-2141.2011.08724.x

Jordet, H., Andersen, D., Blaabjerg, A. H., Bøye, R., Jørgensen, C. R., Freund, C. & Kjølbye, M. (2011). Mentalisering: - mere end et modeord. Psykolog Nyt, 65(17), 14-18. http://www.dp.dk/Psykolognyt/Artikelarkiv.aspx